CVS Health Corporation (LON:0HRS)
75.10
+0.50 (0.67%)
At close: Sep 12, 2025
CVS Health Employees
As of December 31, 2024, CVS Health had 300,000 total employees, including 219,000 full-time and 81,000 part-time employees. The number of employees did not change compared to the previous year.
Employees
300,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
1.08M GBP
Profits / Employee
12.74K GBP
Market Cap
70.18B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 300,000 | 0 | - |
Dec 31, 2023 | 300,000 | 0 | - |
Dec 31, 2022 | 300,000 | 0 | - |
Dec 31, 2021 | 300,000 | 0 | - |
Dec 31, 2020 | 300,000 | 10,000 | 3.45% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
CVS Health News
- 18 days ago - CVS Health to pay more than $12M to settle drug pricing allegations in Massachusetts - Seeking Alpha
- 20 days ago - CVS is up because it faced the pain that's now hitting the rest of managed care, says Jim Cramer - CNBC
- 20 days ago - Jim Cramer talks what is driving CVS higher this year - CNBC
- 20 days ago - Jim Cramer says CVS stock is a buy at these levels. Here's why - CNBC
- 25 days ago - Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug - Investor's Business Daily
- 25 days ago - Only 2 Weeks Away – Register Now! Florida C-suite executives invited to HMG Strategy's 5th Annual C-Level Technology Leadership Summit on September 4 - Benzinga
- 25 days ago - CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans - Benzinga
- 25 days ago - CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans - Benzinga